Core Viewpoint - Invivyd, Inc. will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, indicating active engagement with investors and stakeholders in the biopharmaceutical sector [1][2]. Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on providing protection against serious viral infectious diseases, starting with SARS-CoV-2 [3]. - The company utilizes a proprietary integrated technology platform that is unique in the industry, aimed at assessing, monitoring, developing, and adapting to create best-in-class antibodies [3]. - In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody in its pipeline, highlighting its innovative approach and regulatory progress [3]. Investor Engagement - Management will host investor meetings at the conference, suggesting a proactive approach to investor relations and communication [2]. - A live webcast of the fireside chat will be available on the company's investor website, ensuring transparency and accessibility for investors [2].